Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder of pluripotent stem cells, first described by John Hughes Bennett in 1845. Previously, the treatment options, such as hydroxicarbamide, interferon, busulfan and radiotherapy, only controlled the disease while the novel therapeutic options increased significantly the rate of remissions. Untreated patients in chronic phase (CML-CP) inevitably progressed to CML-BC (blast crisis), an aggressive form of acute leukaemia. Treatment with imatinib mesylate was associated with high response rate and an improved overall survival rate, especially when used in chronic phase. Options for patients resistant to imatinib include either dose increase or use of dasatinib or nilotinib. The objective of the current study was to analyse the impact of the severity and frequency of the adverse drug reactions on treatment results and to determine the treatment costs with imatinib, dasatinib, and nilotinib. An epidemiology and safety model based on information about the registered patients with CML in Bulgaria was established. Treatment costs for each therapy option and the treatment costs of adverse drug reactions (ADR) were determined for 6 months, and 1 year time horizons, from the payer's perspective. The results confirmed that the frequency and severity of ADRs influenced the total pharmacotherapy costs. Nilotinib is the preferred therapeutic and economic alternative.
INTRODUCTION
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell first described by John Hughes Bennett in 1845. The annual incidence of CML is 1.6 cases per 100,000 adults. According to the European Orphan Drug Regulation, 141/2000 CML is classified as a rare diseases (incidence below 1 case per 2 000 adults) (Quintas-Cardama, 2006; Regulation EC, 1999) . CML was the first malignancy that had a specific chromosomal abnormality uniquely linked to it after the discovery of the Philadelphia (Ph) chromosome. Three phases of disease progression are recognized in CML: Chronic phase (CP), accelerated phase (AP), and blast crisis (BC). Each of the three clinical phases of CML is more resistant to treatment than *Corresponding author. E-mail: assena_stoimenova@mail.bg. Tel: +359887749665. Fax: +35929879874. previous phase (Moellman-Coelho et al., 2010) . After a median of 3 to 5 years, untreated patients with CML-CP inevitably progressed to CML-BC, which is a form of acute leukaemia, sometimes refractory to chemotherapy, associated with high poor survival (Besa et al., 2011) . The research and development of new drugs for the treatment of CML continues and opportunities are constantly looked to improve the care for people with CML (Tao et al., 2011; Xie et al., 2011) . Previously, the treatment options, like hydroxicarbamide, interferon, busulfan and radiotherapy, only controlled the disease, while the newly authorised medicinal products significantly increased the rates of remission. The introduction of tyrosine kinase inhibitors (TKI) as a standard treatment of CML was associated with both high response rates and improved overall survival, especially when used in CP, and imatinib was the first of a kind (Baccarani et al., 2006; Kantarjian et al., 2007a) . However, CML patients sometimes become resistant or intolerant to imatinib (Kantarjian et al., 2007b) . Options for those patients include either increasing the imatinib dose or using second-generation tyrosine kinase inhibitors -dasatinib and nilotinib or increase overall survival in patients with imatinib-resistant or intolerant CML. These options are characterized with different safety profiles which reflect the therapy costs (Kantarjian et al., 2007b, c) .
The objective of the current study was to analyse the impact of the severity and frequency of the adverse drug reactions on treatment results and to determine the treatment costs of chronic myeloid leukaemia (CML) treatment with imatinib, dasatinib and nilotinib.
MATERIALS AND METHODS
An epidemiology and safety model based on information about the registered patients with CML in Bulgaria, the expected proportion of patients, resistant or intolerant to imatinib, and the frequency of adverse drug reactions (ADRs) was established (Pilot Epidemiological Study of CML, 2011; Bulgarian National CML patients' registry, 2011). The frequency of ADRs was collected from several clinical trials (Kantarjian et al., 2007a, b, c; Shah et al., 2008; Guilhot et al., 2007; Le Coutre et al., 2008) . Treatment costs for each option and for treatment of ADRs were calculated for 6 months, and 1 year time horizons, from the payer's perspective (Bulgarian Health Insurance Fund). Current haematology therapy guidelines were used to calculate the costs of ADRs. Medicine prices and health care services fees were taken from official registers, published in 2011 (MOH, 2011; Council of Ministers, 2010) .
The total cost of therapy was calculated based on the medicines cost per patient and ADRs cost. The medicines cost was derived as a product from number of tablets per day, number of days and unit tablet price. The model includes all available treatment options in Bulgaria. Costs are calculated according to CIP prices (VAT excl.). Descriptive statistical analysis was performed in case of the price difference and mean price was chosen for cost calculation.
The ADRs treatment cost was calculated by multiplying the frequency of ADRs appearing with the tariff cost of the same ADRs (if it is published), or with the cost of medicines for ADRs therapy. The model is based on the conservative assumption that only one ADR per patient will appear within one year.
The study was revised by the Scientific Ethical Committee of the Medical University in Sofia, Bulgaria.
RESULTS
According to the registry of rare diseases, the patients with CML in Bulgaria are 250 (Pilot Epidemiological Study, 2011; Bulgarian National CML patients' registry, 2011) . The patients' segmentation (imatinib-resistant or intolerant cases) is shown in Table 1 . 60 (0.24) patients are either resistant or intolerance to imatinib and they will need either a higher dose of imatinib (800 mg per day), or dasatinib (100 mg per day), or nilotinib (600 mg per day). 27 of those patients are expected to remain in chronic phase and 9 patients will transit to accelerated phase within the observed one year period.
The frequency of adverse drug reactions (ADRs) is different for the observed medicines (Guilhot et al., 2007; Kantarjian et al., 2007b; Le Coutre et al., 2008; MOH, 2011; Council of Ministers, 2010; Druker et al., 2006; Ovanfors et al., 2011; Wu et al., 2010) and it depends on the disease phase. The ADRs frequency and monthly therapy costs, according to the agreed guidelines and National health insurance fund tariff, are shown in Table  2 .
The most frequent ADRs are the anaemia, neutropenia and thrombocytopenia. Anaemia is treated in ambulatory conditions with erythropoietin, while the neutropenia and thrombocytopenia usually lead to patients' hospitalisation. The most expensive is the neutropenia therapy (2520 BGN/per case). The standard treatment and monthly costs of ADRs per patient are presented in Table 3 .
Addition of the weighed by the frequency of occurrence ADRs cost, with the cost of medicines therapy lead to the possibility of calculating the total treatment cost. The annual treatment cost for patients in chronic phase vary from 65 664 BGN/patient (nilotinid 600 mg), 83 656.80 BGN/patient (dasatinib 100 mg), and 116 983.44 BGN/patient (imatinib 800 mg) per day. Addition of the weighed treatment cost of ADRs, lead to the increase in total treatment case/patient per year to 66 770.90 BGN (nilotinib), 84 960.73 BGN (dasatinib), and 117 586.86 BGN (imatinib), respectively. Similar are the changes in therapy costs for patients in accelerated phase, but nilotinib have shown the lowest frequency of adverse drug reactions in both disease phases (Table 3 ). As evident from Table 4 , the disease progression affects in a greater extend the therapy results and cost with dasatinib due to both, the higher frequency of severe ADRs and higher therapy cost.
DISCUSSION
The main findings in our study are that nilotinib has lower cost of therapy considering also the cost and incidence of ADRs and it should be considered for reimbursement from the National health insurance fund for patients with CML, intolerant or resistant to imatinib or dasatinib. Adverse drug reactions should be evaluated carefully for all patients when choosing the appropriate TKI. Taking their frequency and costs into account in the budget, impact analysis adds valuable information to the decision makers. The choice of high dose (600 mg), imatinib, dasatinib and nilotinib as alternative therapies for patients, intolerant or resistant to imatinib standard doses (400 mg) is due to the fact that these are the only therapies provided to all patients with CML in our country. Previously used treatment options, such as hydroxicarbamide, interferon, busulfan and radiotherapy, only controlled the disease and thus they were abandoned for these groups of patients. Stem cell transplantation or the use of investigational drugs is currently no options for patients with CML in Bulgaria. Our study was inspired by the recent introduction of the nilotinob in the national positive drug list and the existing differences in the safety profile of the studied medicines. We aimed to see if this novel medicine will be affordable for our health care system. Our results confirmed a nilotinib as first-line therapy cost-effectiveness study made from Swedish health care system perspective (Ovanfors et al., 2011) . Similar results are also reported by Wu et al. (2010) who confirmed that nilotinib patients are more adherent and are source of less healthcare resource utilization, resulting in medical service cost savings, compared to dasatinib patients. Special attention to the ADRs, presence of mutations in the BCR-ABL kinase domain, and cost was given by Harnicar to support the choice of a TKI for CML patients (Harnicar, 2011) . Drug interactions should be evaluated for all patients when choosing the appropriate TKI.
We focused on nilotinib as second line options because it is the most likely to be reimbursed in the country. Our study has some limitations due to the fact that it focuses on the ADRs incidence and their costs only.
Conclusion
The frequency and severity of ADRs influence the total pharmacotherapy cost for CML in Bulgaria. Nilotinib appeared to be a less costly therapeutic choice for patients in chronic and accelerated CML phase from the point of view of the health insurance fund, even when the ADRs pharmacotherapy costs are considered.
